Modality
Vaccine
MOA
CD47i
Target
MALT1
Pathway
Incretin
ObesityRSVCKD
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
Nov 2018
→ Oct 2030
Phase 2Current
NCT03722596
1,868 pts·Obesity
2022-09→2030-10·Not yet recruiting
NCT05934060
113 pts·CKD
2018-11→2026-06·Active
1,981 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-02-062mo agoEMA Filing· Obesity
2026-06-072mo awayPh3 Readout· CKD
2030-10-274.6y awayPh3 Readout· Obesity
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Active
P2/3
Not yet…
Catalysts
EMA Filing
2026-02-06 · 2mo ago
Obesity
Ph3 Readout
2026-06-07 · 2mo away
CKD
Ph3 Readout
2030-10-27 · 4.6y away
Obesity
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03722596 | Phase 2/3 | Obesity | Not yet recr... | 1868 | EDSS |
| NCT05934060 | Phase 2/3 | CKD | Active | 113 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |